Literature DB >> 1659958

Pathogenetic role of vascular angiotensin-converting enzyme in the spontaneously hypertensive rat.

H Okunishi1, T Kawamoto, Y Kurobe, Y Oka, K Ishii, T Tanaka, M Miyazaki.   

Abstract

1. This study was undertaken to examine the possibility that the level of angiotensin-converting enzyme (ACE) increases in vascular tissue, and that this may participate in the pathogenesis of hypertension in spontaneously hypertensive rat (SHR). 2. In SHR, at the established hypertensive stage, the prolonged antihypertensive effect induced by a single oral dose of spirapril was closely correlated to the long-lasting inhibition of ACE in aortae and mesenteric arteries. In contrast, ACE in plasma, lung, heart and kidney recovered from inhibition faster than in vessels. 3. Prolonged daily oral treatment of SHR with spirapril, initiated at the age of 8 weeks and continued for 8 weeks, prevented the development of hypertension with concomitant decrease in aortic ACE activity. Blood pressure continued to be suppressed after the drug was withdrawn, as did the aortic ACE activity. 4. Spontaneously hypertensive rats developed hypertension with age as well as with the increase in aortic ACE activity which became higher with age than that of Wistar-Kyoto (WKY) normotensive control rats. On the contrary, ACE activity in plasma and lung of SHR was substantially lower than that of WKY at any age from 4 to 20 weeks old. Brain ACE activity of SHR did not differ from that of WKY at any age. Aged SHR showed the lower enzyme activity in the kidney compared with that of age-matched WKY. 5. Our results support the hypothesis that increased vascular ACE may play an essential role in the development and maintenance of hypertension in SHR.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659958     DOI: 10.1111/j.1440-1681.1991.tb01639.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  3 in total

Review 1.  Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.

Authors:  S Noble; E M Sorkin
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

2.  Cardiovascular changes in spontaneously hypertensive rats are improved by chronic treatment with zofenopril.

Authors:  M Gómez-Roso; M J Montero; R Carrón; M A Sevilla
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

3.  In Silico identification of angiotensin-converting enzyme inhibitory peptides from MRJP1.

Authors:  Rana Adnan Tahir; Afsheen Bashir; Muhammad Noaman Yousaf; Azka Ahmed; Yasmine Dali; Sanaullah Khan; Sheikh Arslan Sehgal
Journal:  PLoS One       Date:  2020-02-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.